Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardio-Pulmonary Bypass.

Trial Profile

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardio-Pulmonary Bypass.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Pexelizumab (Primary)
  • Indications Coronary disorders; Myocardial infarction
  • Focus Registrational; Therapeutic Use
  • Acronyms PRIMO-CABG
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top